» Articles » PMID: 38564480

SARS-CoV-2 Omicron Subvariants Do Not Differ Much in Binding Affinity to Human ACE2: A Molecular Dynamics Study

Overview
Journal J Phys Chem B
Specialty Chemistry
Date 2024 Apr 2
PMID 38564480
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of the variant of concern Omicron (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exacerbates the COVID-19 pandemic due to its high contagious ability. Studies have shown that the Omicron binds human ACE2 more strongly than the wild type. The prevalence of Omicron in new cases of COVID-19 promotes novel lineages with improved receptor binding affinity and immune evasion. To shed light on this open problem, in this work, we investigated the binding free energy of the receptor binding domain of the Omicron lineages BA.2, BA.2.3.20, BA.3, BA4/BA5, BA.2.75, BA.2.75.2, BA.4.6, XBB.1, XBB.1.5, BJ.1, BN.1, BQ.1.1, and CH.1.1 to human ACE2 using all-atom molecular dynamics simulation and the molecular mechanics Poisson-Boltzmann surface area method. The results show that these lineages have increased binding affinity compared to the BA.1 lineage, and BA.2.75 and BA.2.75.2 subvariants bind ACE2 more strongly than others. However, in general, the binding affinities of the Omicron lineages do not differ significantly from each other. The electrostatic force dominates over the van der Waals force in the interaction between Omicron lineages and human cells. Based on our results, we argue that viral evolution does not further improve the affinity of SARS-CoV-2 for ACE2 but may increase immune evasion.

Citing Articles

Neuropilin-1 Protein May Serve as a Receptor for SARS-CoV-2 Infection: Evidence from Molecular Dynamics Simulations.

Nguyen H, Hieu H, Nguyen T, Nhung N, Li M J Phys Chem B. 2024; 128(29):7141-7147.

PMID: 39010661 PMC: 11284781. DOI: 10.1021/acs.jpcb.4c03119.

References
1.
Premkumar L, Segovia-Chumbez B, Jadi R, Martinez D, Raut R, Markmann A . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48). PMC: 7292505. DOI: 10.1126/sciimmunol.abc8413. View

2.
Williams A, Zhan C . Fast Prediction of Binding Affinities of the SARS-CoV-2 Spike Protein Mutant N501Y (UK Variant) with ACE2 and Miniprotein Drug Candidates. J Phys Chem B. 2021; 125(17):4330-4336. PMC: 8084269. DOI: 10.1021/acs.jpcb.1c00869. View

3.
Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y . Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe. 2022; 30(11):1540-1555.e15. PMC: 9578327. DOI: 10.1016/j.chom.2022.10.003. View

4.
Trunfio M, Portesani F, Vicinanza S, Nespoli P, Traverso F, Cortese G . Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia. Lung. 2022; 200(5):573-577. PMC: 9483268. DOI: 10.1007/s00408-022-00566-7. View

5.
Peka M, Balatsky V . The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex. Future Virol. 2023; . PMC: 10089296. DOI: 10.2217/fvl-2022-0152. View